Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Steve D. who wrote (4727)	1/16/2000 5:30:00 PM
From: KAKALAK	Read Replies (1) \| Respond to of 4891

FROM THE RB BOARD: By: shaggydogs Reply To: 2385 by MisterFurter Sunday, 16 Jan 2000 at 12:42 PM EST Post # of 2388 MisterFurter, I think that your impression that ADVR doesn't have data to submit to the FDA for approval may be wrong. There is the Dominican Republic, Barbados, and Argentina data, where two of these sets can be considered clinical in nature, along with other data like that referred to by Dr. Hirschman in his November presentation, concerning PWAs from New York and Paris whose conditions were vastly improved by mixing Substance R with the HAART cocktail. EOM Regarding the PWA's from the US and France: We all know that FDA INDA'a are to be submitted in short order. Was there any significance to the French PWA being French or for that matter European? Is ADVR applying to the French or EEC regulating bodies for their INDA equivalents? Do these regulating bodies simply accept FDA approval or do they require their own submissions? Thanks